The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

References

• Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63:S8–14
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Rev Neurother 2006;6:333–46
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125–32
   PubMed Web of Science ®Google Scholar
• Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306–9
   PubMed Web of Science ®Google Scholar
• Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005;5:721–7
   PubMedGoogle Scholar
• Beutler E, Sipe J, Romine J, et al. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin Hematol 1996;33:45–52
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994;120: 784–91
   Google Scholar
• Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985;75:377–83
   PubMed Web of Science ®Google Scholar
• Lindemalm S, Liliemark J, Juliusson G, et al. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Cancer Lett 2004;210:171–7
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737–43
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5’-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993;81:597–601
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe JC, Romine JS, et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716–20
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2’-deoxyadenosine. Proc Natl Acad Sci U S A 1984;81: 2232–6
   Google Scholar
• Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992;80: 587–92
   Google Scholar
• Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995;13:989–95
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–26
   PubMed Web of Science ®Google Scholar
• Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin’s lymphomas: results of a Japanese phase II study. Int J Hematol 2004;80:267–77
   PubMed Web of Science ®Google Scholar
• Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001;19:2804–11
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12:2694–8
   PubMed Web of Science ®Google Scholar
• Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997;32:120–31
   PubMed Web of Science ®Google Scholar
• Valencak J, Trautinger F, Fiebiger WC, et al. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxy adenosine. Ann Hematol 2002;81:662–5
   PubMed Web of Science ®Google Scholar
• Schirmer M, Mur E, Pfeiffer KP, et al. The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial. Scand J Rheumatol 1997;26:376–9
   PubMed Web of Science ®Google Scholar
• Davis JC, Jr., Austin H, 3rd, Boumpas D, et al. A pilot study of 2-chloro-2’-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998;41: 335–43
   Google Scholar
• Duchini A, Younossi ZM, Saven A, et al. An open-label pilot trial of cladribine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000;31:292–6
   PubMed Web of Science ®Google Scholar
• Pless M, Gratwohl A, Tichelli A, et al. 2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease. Blood 1994;84: 987–9
   Google Scholar
• Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2’-deoxyadenosine in humans. Cancer Res 1991;51:5570–2
   PubMed Web of Science ®Google Scholar
• Munafo A, Tran D, Marcus S. Pharmacokinetics of oral cladribine (Mylinax) after administration in patients with multiple sclerosis. In: 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis–10th Annual Meeting of the American Committee for Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece; 2005.
   Google Scholar
• Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2’-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 1993;44: 579–82
   Google Scholar
• Kearns CM, Blakley RL, Santana VM, et al. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 1994;54:1235–9
   PubMed Web of Science ®Google Scholar
• Marks R, Richardson R, Reid J. A Phase I and pharmacologic study of 2-chlorodeoxyadenosine in patients with advanced solid tumors (abstract). Proc Am Soc Clin Oncol 1994;13: 416
   Google Scholar
• Albertioni F, Pettersson B, Reichelova V, et al. Analysis of 2-chloro-2’-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. Ther Drug Monit 1994;16:413–18
   PubMed Web of Science ®Google Scholar
• Grieb P, Kamienowski J, Janisz M, et al. Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns. Int J Hematol 2001;74:421–7
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000;54: 1145–55
   Google Scholar
• Selby R, Brandwein J, O’Connor P. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can J Neurol Sci 1998;25:295–9
   Google Scholar
• Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit 2001;7:93–8
   Google Scholar
• Stelmasiak Z, Bartosik-Psujek H, Belniak-Legiec E, et al. The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS). Ann Univ Mariae Curie Sklodowska [Med] 2000;55:221–5
   PubMedGoogle Scholar
• Romine JS, Sipe JC, Koziol JA, et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35–44
   PubMedGoogle Scholar
• Sipe JC, Romine JS, Koziol JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9–13
   PubMed Web of Science ®Google Scholar
• Beutler E, Koziol JA, McMillan R, et al. Marrow suppression produced by repeated doses of cladribine. Acta Haematologica 1994;91:10–5
   PubMed Web of Science ®Google Scholar
• Stelmasiak Z, Solski J, Nowicki J, et al. Cladribine (2-CdA) in treatment of remitting-relapsing multiple sclerosis: 2-year double-blind crossover placebo-controlled study. Mult Scler 1997;3:348
   Google Scholar
• Niezgoda A, Losy J, Mehta PD. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol (Warsz) 2001;60: 225–8
   Google Scholar
• Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340: 952–6
   Google Scholar
• Martinez-Rodriguez JE, Cadavid D, Wolansky LJ, et al. Cladribine in aggressive forms of multiple sclerosis. Eur J Neurol 2007;14: 686–9
   Google Scholar
• Solanky M, Van Engel D, Wolansky L, et al. Aggressive central nervous system demyelination in an adolescent. Rev Neurol Dis 2005;2:35–8
   PubMedGoogle Scholar
• Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry 2001;70: 574–9
   Google Scholar
• Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004;251:v42–9
   PubMedGoogle Scholar
• Beutler E, Piro LD, Savan A. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991;5: 1–8
   Google Scholar
• Cook SD, Picone MA and the Cladribine Clinical Study Group. Safety and tolerability of cladribine in the treatment of patients with multiple sclerosis (MS) in double-blind, placebo-controlled clinical trials. Neurology 1999;(Suppl 2):A496–7
   Google Scholar
• World Health Organization. Adherence to long-term therapies: evidence for action. 2003
   Google Scholar
• Samuel L, Lowenstein EJ. Recurrent injection site reactions from interferon beta 1-b. J Drugs Dermatol 2006;5:366–7
   PubMedGoogle Scholar
• Brazeau GA, Cooper B, Svetic KA, et al. Current perspectives on pain upon injection of drugs. J Pharm Sci 1998;87: 667–77
   PubMed Web of Science ®Google Scholar
• Haynes R, Yao X, Degani A, et al. Interventions for enhancing medication adherence. The Cochrane Database of Systematic Reviews 2001
   Google Scholar
• Bakshi R, Minagar A, Jaisani Z, et al. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005;2:277–303
   PubMedGoogle Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–7
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31
   PubMed Web of Science ®Google Scholar
• The IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45: 1277–85
   Google Scholar
• Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004;63: S47–54
   PubMed Web of Science ®Google Scholar